Amounts of bFGF in supernatants of FaDu and HeLa cells measured via ELISA, treated with WX-UK1, Galardin
, and Celecoxib
® as single drugs and with combinations thereof. The COX-2 inhibitor Celecoxib® displayed the greatest effects as a single drug and in combination with WX-UK1 and/or Galardin®. Triple medication was neither for FaDu nor for HeLa cells more effective than Celecoxib® alone, pinpointing that COX-2 inhibition was instrumental in the reduction of bFGF release by tumour cells.